ArticleJournal of advanced research2026
The pro-cancer and immunosuppressive activity of macrophage-transformed cancer-associated fibroblasts in oral squamous cell carcinoma.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Beyond EMT: Mesenchymal drift as an emerging driver of stromal-immune reprogramming in prostate cancer.iScience · 2026Review
- Macrophage-to-myofibroblast transition-derived itaconate promotes bone metastasis in lung cancer through targeting of HSPA8.Experimental & molecular medicine · 2026Article
- Single cell atlas decodes the molecular dynamics of scar repair after human rotator cuff tear.Bone research · 2026Article
- Single-cell sequencing-guided design of synergistic chemo-immunotherapy nanodrugs for cGAS-STING activation in prostate cancer therapy.Journal of nanobiotechnology · 2026Article
- Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma.Research (Washington, D.C.) · 2026Article
- Innate immune signaling-driven myeloid remodeling in cancer: inflammatory amplification, immune suppression, and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer-associated fibroblasts (CAFs), as a crucial component of the tumor microenvironment (TME), exhibit heterogeneity, and macrophage-myofibroblast transition (MMT) has been demonstrated to be one of the origins of CAFs. However, the existence and functional features of MMT cells (MMTs) relative to general CAFs in tumors, especially in oral squamous cell carcinoma (OSCC), have not been fully revealed.
objectivesThis study is intended to understand the origin and functional features of MMT and the underlying mechanisms of its formation and functionality.
methodsThe presence of MMT in OSCC was determined through single-cell RNA sequencing (scRNA-seq) analysis, immunofluorescence of OSCC pathological sections, and flow cytometry of OSCC allograft tumors. The origin and potential formation mechanism of MMT were investigated through scRNA-seq pseudotime analysis and in vitro induction of BMDM. Subcutaneous OSCC tumor model mice were employed, in combination with macrophage depletion, adoptive transfer of BMDM-derived MMTs (BMDM-MMTs), and flow cytometry and immunofluorescence staining were carried out to investigate the role of MMT in OSCC. Further in vivo and in vitro experiments, in conjunction with scRNA-seq, were performed to explore the possible mechanism through which MMT exerts its function in OSCC.
resultsMMT was confirmed to exist in OSCC. The addition of tumor-conditioned medium and exogenous TGFβ1 promoted MMT. Meanwhile, it was found that the adoptive transfer of BMDM-MMT significantly enhanced tumor progression and fibrosis in OSCC tumor-bearing mice. Single-cell sequencing and in vitro and in vivo experiments jointly verified that MMTs promoted MDSCs homing and functionality via CXCL10 to promote the immunosuppressive microenvironment of the tumor.
conclusionThese results imply that macrophages can transform into CAFs via the activated smad3 pathway by TGFβ1 derived from tumor cells in OSCC, and MMT exerts protumoral and immunosuppressive functions in OSCC through the CXCL10 pathway. MMT may become a novel therapeutic target for the immunotherapy of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.